TENX

Rating sellAI Memo

Tenax Therapeutics

As of 2026-08-11/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

sell

Confidence

medium

Horizon

—

Key catalyst

FDA Type C meeting and revised development path • 2026-11-09

Base target: $1 / p=50% prob

Biggest risk

Missing both primary and key secondary endpoints materially weakens the registrational thesis. The subgroup and biomarker results are exploratory with nominal p-values, and the FDA may require a redesigned or otherwise extended development strategy. Continued clinical spending and future financing risk remain meaningful.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The trial produced potentially meaningful exploratory signals, including a 26.3-meter improvement in the lower-baseline-walk subgroup, a 49% relative NT-proBNP reduction, and a 3.5 mmHg RVSP reduction. Cash of $118.0 million as of June 30, 2026 was expected to fund operations through Q2 2028, preserving time for FDA discussions and LEVEL-2 execution [#8-K-2026-08-10][#SEC-8K-2026-07-31].

Research note

Recommendation

sell

Confidence

medium

As of

2026-08-11

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

LEVEL Phase 3 topline failure resets the thesis
LEVEL-2 enrollment and follow-up execution
The trial produced potentially meaningful exploratory signals, including a 26.3-meter improvement in the lower-baseline-walk subgroup, a 49% relative NT-proBNP reduction, and a 3.5 mmHg RVSP reduction.

BearKey bullets

Exploratory subgroup and biomarker findings may not support regulatory approval or a revised registrational path.
FDA feedback could require additional trials, protocol changes, or delay.
LEVEL failed its primary and key secondary endpoints.

WatchKey bullets

FDA Type C meeting and revised development path

Summary

High-level snapshot

Recommendation

sell

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=50%)

Target spread vs base: +137% / -53%

Scenario probabilities

Bull Target: $2 (p=20%)Base Target: $1 (p=50%)Bear Target: $0 (p=30%)

Commentary

Sentiment is sharply negative after the August 10 LEVEL readout; trusted-news coverage described the shares as sinking after the trial result. The packet does not establish an exact pre-event comparison or provide analyst revisions, so the immediate market reaction is clear but forward valuation remains uncertain. The setup is a low-coverage, high-volatility monitoring situation rather than a high-conviction recovery thesis.

As of 2026-08-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

LEVEL Phase 3 topline failure resets the thesis
LEVEL-2 enrollment and follow-up execution

Scenarios

Bull Target (Scenario probability)

$2 / p=20% prob

Base Target (Scenario probability)

$1 / p=50% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-08-11 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.80

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-09
FDA Type C meeting and revised development path
Tenax intends to request an FDA Type C meeting to discuss revisions to the ongoing registrational development of TNX-103. Regulatory feedback is the key near-term determinant of whether the subgroup findings support a viable path forward [#8-K-2026-08-10].
Prob 70.00% • Move 25.00% • Priced-in 10.00%

Short-term Catalysts

Next few weeks

LEVEL Phase 3 topline failure resets the thesis
2026-08-11
The August 10 filing reported that LEVEL missed its primary 6-minute walk-distance endpoint and key secondary KCCQ endpoint. Exploratory subgroup and biomarker signals were positive but nominal, leaving the readout predominantly negative [#8-K-2026-08-10].
Prob 100% • Move -20% • Priced-in 85%

Long-term Catalysts

Months to a year

LEVEL-2 enrollment and follow-up execution
2027-12-31
The company previously expected LEVEL-2 enrollment completion by the end of 2027, while the LEVEL open-label extension remains ongoing. Execution, durability, and any protocol changes will determine residual pipeline value after the LEVEL miss [#SEC-8K-2026-07-31].
Prob 50% • Move 35% • Priced-in 15%

Risks

Exploratory subgroup and biomarker findings may not support regulatory approval or a revised registrational path.
FDA feedback could require additional trials, protocol changes, or delay.
LEVEL failed its primary and key secondary endpoints.
LEVEL-2 enrollment and development strategy may be revised after the LEVEL result.
Low analyst coverage and loose peers reduce confidence in valuation benchmarking.
Ongoing R&D burn and eventual financing could create dilution risk.

Peers

Symbol	Summary
ATYR	Same-sector small-cap biotech comparator; useful for event-volatility framing, but the packet provides no direct PH-HFpEF read-through.
RNXT	Similar-market-cap clinical biotech with milestone-driven valuation; a loose execution-risk comparator rather than a direct therapeutic peer.
SCYX	Same-sector small-cap biotech comparator; financing and clinical execution risks are relevant, but indication-level comparability is limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-11

Loading AI feed…

Symbol

Summary

ATYR

Same-sector small-cap biotech comparator; useful for event-volatility framing, but the packet provides no direct PH-HFpEF read-through.

RNXT

Similar-market-cap clinical biotech with milestone-driven valuation; a loose execution-risk comparator rather than a direct therapeutic peer.

SCYX

Same-sector small-cap biotech comparator; financing and clinical execution risks are relevant, but indication-level comparability is limited.